This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.32% per year. These returns cover a period from January 1, 1988 through July 31, 2023.

• Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams.
• More value-oriented stocks tend to represent financial services, utilities, and energy stocks.
• Plus, NBIX info will be updated daily in your Zacks.com Portfolio Tracker – also free.
• Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed.

Upgrade to MarketBeat All Access to add more stocks to your watchlist. One share of NBIX stock can currently be purchased for approximately $113.77. Click the link below and we’ll send you MarketBeat’s list of seven stocks and why their long-term outlooks are very promising.

Sales & Book Value

It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Compare
NBIX’s historical performance
against its industry peers and the overall market. NBIX’s beta can be found in Trading Information at the top of this page. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

• Morningstar analysts hand-select direct competitors or comparable companies to
  provide context on the strength and durability of NBIX’s
  competitive advantage.
• Neurocrine Biosciences’s earnings are expected to grow from $2.17 per share to $4.87 per share in the next year, which is a 124.42% increase.
• Netflix is graded C on this front, indicating that it is trading at par with its peers.
• There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score.

Style is calculated by combining value and growth scores, which are first individually calculated. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. While earnings growth is arguably the most superior indicator of a company’s financial health, nothing happens as such if a business isn’t able to grow its revenues.

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2023 Financial Results

Neurocrine Biosciences has generated $1.73 earnings per share over the last year ($1.73 diluted earnings per share) and currently has a price-to-earnings ratio of 65.8. Earnings for Neurocrine Biosciences are expected to grow by 124.42% in the coming year, from $2.17 to $4.87 per share. Neurocrine Biosciences has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, November 7th, 2023 based off prior year’s report dates. We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends.

ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank.

How we use your personal data

Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements. Neurocrine Biosciences’s earnings are expected to grow from $2.17 per share to $4.87 per share in the next year, which is a 124.42% increase. In Neurocrine’s study, adults with CAH who took crinecerfont had a statistically significant decrease in their daily glucocorticoids dosage, while still keeping their androgen levels under control. Traditionally, managing CAH requires daily doses of steroid hormones called glucocorticoids and suppressing androgen hormones. Left unchecked, children with CAH could produce too much testosterone, leading to rapid growth and early puberty.

Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Netflix is rated Zacks Rank #3 (Hold).

Neurocrine Biosciences Earnings – Frequently Asked Questions

Neurocrine Biosciences last issued its quarterly earnings data on August 1st, 2023. The reported $0.95 earnings per share for the quarter, beating analysts’ transaction multiples consensus estimates of $0.77 by $0.18. The company earned $452.70 million during the quarter, compared to analysts’ expectations of $448.29 million.

The facts discussed here and much other information on Zacks.com might help determine whether or not it’s worthwhile paying attention to the market buzz about Netflix. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term. Netflix is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade. Compared to the Zacks Consensus Estimate of $8.26 billion, the reported revenues represent a surprise of -0.93%.

About Neurocrine Biosciences (NASDAQ:NBIX) Stock

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. Plus, NBIX info will be updated daily in your Zacks.com Portfolio Tracker – also free.

Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. The scores are based on the trading styles of Value, Growth, and Momentum. https://1investing.in/ There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security.

FDA Greenlights Expanded Use Of Neurocrine Biosciences’ Ingrezza: Analysts Weigh In Depression Warning

For the next fiscal year, the consensus earnings estimate of $15.72 indicates a change of +31.9% from what Netflix is expected to report a year ago. 21 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Neurocrine Biosciences in the last twelve months. There are currently 5 hold ratings and 16 buy ratings for the stock.

In the case of Netflix, the consensus sales estimate of $8.53 billion for the current quarter points to a year-over-year change of +7.6%. The $33.73 billion and $38.29 billion estimates for the current and next fiscal years indicate changes of +6.7% and +13.5%, respectively. Neurocrine Biosciences, Inc. (NBIX) receives a strong valuation score of 94 from InvestorsObserver analysis. Our proprietary scoring system considers the overall health of the company by looking at the stock’s price, earnings, and growth rate to determine if it represents a good value.

The company’s three late stage clinical programs are elagolix which is hormone releasing antagonist for women’s health, opicapone which is an inhibitor for parkinson’s patients, and ingrezza for tourette syndrome. Netflix (NFLX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Neurocrine Biosciences has not confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, November 7th, 2023 based off last year’s report dates. Enter your email address below to receive the latest headlines and analysts’ recommendations for your stocks with our free daily email newsletter. Style is an investment factor that has a meaningful impact on investment risk and returns.